Go Pro
NASDAQ:QTEX

Inspira Technologies OXY B.H.N. Q2 2026 Earnings Report

Inspira Technologies OXY B.H.N. logo
$0.78 +0.10 (+15.04%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 +0.06 (+7.44%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inspira Technologies OXY B.H.N. EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Inspira Technologies OXY B.H.N. Revenue Results

Actual Revenue
$0.78 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inspira Technologies OXY B.H.N. Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Inspira Technologies OXY B.H.N. Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
QTREX Quantum Reports First Half 2026 Financial Results
See More Inspira Technologies OXY B.H.N. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inspira Technologies OXY B.H.N.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inspira Technologies OXY B.H.N. and other key companies, straight to your email.

About Inspira Technologies OXY B.H.N.

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX). is an Israeli medical technology company focused on developing advanced respiratory-support systems for patients experiencing acute respiratory failure. The company’s technology is intended to support blood oxygenation and carbon-dioxide removal while potentially reducing reliance on invasive mechanical ventilation.

Its principal product platform is the INSPIRA ART system, an extracorporeal respiratory-support technology designed to oxygenate blood outside the body and return it to the patient. Inspira has also developed the HYLA blood sensor, which is intended to provide continuous monitoring of blood parameters during respiratory-support treatment. The company’s products remain subject to applicable regulatory review and authorization in the markets where they may be offered.

Inspira Technologies was founded in Israel and conducts its development activities there, while pursuing regulatory and commercial opportunities in international healthcare markets. The company is led by Dagi Ben-Noon, its founder and chief executive officer.

View Inspira Technologies OXY B.H.N. Profile